These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15946144)

  • 21. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C
    Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
    Mansour NM; Hashash JG; El-Halabi M; Ghaith O; Maasri K; Sukkarieh I; Malli A; Sharara AI
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):865-70. PubMed ID: 21811161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
    Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
    Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
    Perri F; Festa V; Clemente R; Villani MR; Quitadamo M; Caruso N; Bergoli ML; Andriulli A
    Am J Gastroenterol; 2001 Jan; 96(1):58-62. PubMed ID: 11197288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
    Shimoyama T; Fukuda S; Mikami T; Fukushi M; Munakata A
    J Gastroenterol; 2004 Oct; 39(10):927-30. PubMed ID: 15549444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
    Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
    Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
    Nishikawa K; Sugiyama T; Ishizuka J; Kudo T; Komatsu Y; Katagiri M; Sukegawa M; Kagaya H; Kudo M; Kato M; Takeda H; Toyota J; Asaka M
    J Gastroenterol; 1999; 34 Suppl 11():72-5. PubMed ID: 10616770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
    Murakami K; Sato R; Okimoto T; Nasu M; Fujioka T; Kodama M; Kagawa J
    Aliment Pharmacol Ther; 2003 Jan; 17(1):119-23. PubMed ID: 12492740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study).
    Koizumi W; Tanabe S; Nakatani K; Ishido K; Nishimura K; Azuma M; Ae T; Sasaki T; Higuchi K; Katada C; Nakayama N; Saigenji K
    J Clin Pharm Ther; 2010 Jun; 35(3):303-7. PubMed ID: 20831531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
    Gessner BD; Bruce MG; Parkinson AJ; Gold BD; Muth PT; Dunaway E; Baggett HC
    Clin Infect Dis; 2005 Nov; 41(9):1261-8. PubMed ID: 16206100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.
    Romano M; Marmo R; Cuomo A; De Simone T; Mucherino C; Iovene MR; Montella F; Tufano MA; Del Vecchio Blanco C; Nardone G
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):273-8. PubMed ID: 15017668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
    Lüth S; Teyssen S; Kölbel CB; Singer MV
    Z Gastroenterol; 2001 Apr; 39(4):279-81, 284-5. PubMed ID: 11367976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
    Yang KC; Wang GM; Chen JH; Chen TJ; Lee SC
    J Formos Med Assoc; 2003 Dec; 102(12):857-62. PubMed ID: 14976565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
    Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
    Wong BC; Wong WM; Yee YK; Hung WK; Yip AW; Szeto ML; Li KF; Lau P; Fung FM; Tong TS; Lai KC; Hu WH; Yuen MF; Hui CK; Lam SK
    Aliment Pharmacol Ther; 2001 Dec; 15(12):1959-65. PubMed ID: 11736727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
    Miwa H; Yamada T; Sato K; Ohta K; Ohkura R; Murai T; Nagahara A; Takei Y; Ogihara T; Sato N
    Dig Dis Sci; 2000 Jan; 45(1):77-82. PubMed ID: 10695617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
    Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
    Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.
    Kudo T; Fujinami H; Ando T; Nishikawa J; Ogawa K; Hosokawa A; Orihara T; Murakami J; Takahara T; Sugiyama T
    Helicobacter; 2012 Aug; 17(4):277-81. PubMed ID: 22759327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.